Castle Biosciences (NASDAQ:CSTL) reported fourth-quarter revenue of $87.0 million and full-year 2025 revenue of $344.2 ...
Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results